Novel N-(benzothiazol/oxazol-2-yl)-2-[(5-(phenoxymethyl)-4-aryl-4H-1,2,4-triazol-3-yl)thio] acetamide derivatives (5a-n) were synthesized and investigated for in vitro anti-inflammatory activity and p38α MAP kinase inhibition. Compounds showing good in vitro activities (5a, 5b, 5d, 5e, 5i, 5k and 5l) were studied for their in vivo anti-inflammatory activity using carrageenan induced rat paw edema model. Compound 5b emerged as the most active compound with an edema inhibition of 84.43%. It also showed improved GI safety profile with lower ulcer severity index and lipid peroxidation potential. Also, p38α MAP kinase assay of 5b showed superior inhibitory potency (IC₅₀:0.031 ± 0.14 µM) than the standard SB 203580 (IC₅₀:0.043 ± 0.14 µM). To predict their binding mode compounds were also docked against p38α MAP kinase enzyme. Compound 5b and SB 203580 showed hinge region interaction with MET 109.

新的N-（苯并噻唑/恶唑-2-基）-2-[（5-（苯氧基甲基）-4-芳基-4H-1,2,4-三唑-3-基）硫代]乙酰胺衍生物（5a-n）合成并研究其体外抗炎活性和p38αMAP激酶抑制作用。使用角叉菜胶诱导的大鼠爪水肿模型研究了显示出良好体外活性（5a，5b，5d，5e，5i，5k和5l）的化合物的体内抗炎活性。化合物5b出现为最活跃的化合物，具有84.43％的水肿抑制作用。它还显示出改善的胃肠道安全性，具有较低的溃疡严重程度指数和脂质过氧化潜力。同样，5b的p38αMAP激酶测定显示出比标准SB 203580（IC ₅₀：0.043±0.14 µM）优越的抑制力（IC ₅₀：0.031 ±0.14 µM）。为了预测它们的结合模式，化合物也与p38αMAP激酶对接。化合物5b和SB 203580显示出与MET 109的铰链区相互作用。